Biotech’s Predictions For 2016 For The Cannabis Industry

5: Investors will embrace Portola Pharmaceuticals Last year, I focused on the upside potential for Alkermes, Inc . , a company developing therapies for central nervous system disorders that I felt was undervalued based on its pipeline potential. This year, I think it’s Portola Pharmaceuticals that investors are under-estimating. Admittedly,... more →
Posted in: Investing